Capri Holdings Ltd vs Nuwellis Inc — how do they compare? Capri Holdings Ltd trades at $14.73 (market cap $1.64B), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: Capri Holdings Ltd is far larger — about 745.5× Nuwellis Inc's market cap, and Capri Holdings Ltd is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Capri Holdings Ltd for 41 Days and Nuwellis Inc for 26 Days on average.
| CPRI | NUWE | |
|---|---|---|
Market Cap | $1.64B | $2.20M |
Volume | 1,891,363 | 121,544 |
Sector | Consumer Cyclical | Health |
52-Week High | $27.66 | $146.65 |
52-Week Low | $12.71 | $0.68 |
Typical Hold Time | 41 Days | 26 Days |
Enterprise Value | $2.92B | -$1.52M |
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $14.68, up slightly by 0.07% today, with a bearish technical signal from moving averages but neutral oscillators. The stock has beaten earnings estimates for the last three quarters, with Q3 2026 results pending. Revenue declined to $4.44 billion in 2025, and net income was negative $1.18 billion, though 2026 projections show a return to profitability. The company's balance sheet shows total assets of $5.21 billion against liabilities of $4.84 billion, with a high ROE of 252.89% but modest net income margin of 4.44%.
The outlook is mixed: analyst consensus is a Buy with a $20.57 price target, implying significant upside, but recent news highlights turnaround risks and a lowered 2027 sales view. Key risks include Michael Kors brand weakness and competitive pressures in the luxury sector. Cash flow trends show consistent negative net cash flow, adding to execution concerns amid efforts to revitalize brands.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →